Unquoted Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	10/27/2003 4:02:47 AM
From: nigel bates	of 253

Microbia Announces Successful Development of Advanced Biomanufacturing Process for Teva Pharmaceuticals CAMBRIDGE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Microbia, Inc. today announced that it has successfully applied its Precision Engineering(TM) technology to improve the production efficiency of a key manufacturing process. The advance resulted from a collaboration Microbia initiated with Teva Pharmaceutical Industries Ltd. in September 2002 to develop improved, higher-yielding biomanufacturing processes using Microbia's Precision Engineering(TM) technology. Teva has validated the enhanced productivity of the resulting microbial fermentation in its manufacturing facility and plans to use the new bioprocess in commercial production. This represents the first commercial manufacturing use of Microbia's Precision Engineering(TM) technology and triggers a series of undisclosed payments from Teva to Microbia. Precision Engineering(TM) is a comprehensive, systems-based approach to engineering the regulatory circuitry of microbes used in industrial-scale production of pharmaceuticals and fine chemicals. Benefits of Precision Engineering(TM) include reduced process-improvement cycle time and the ability to increase production without having to expand biomanufacturing facilities. "We are very pleased that our Precision Engineering(TM) technology has been validated at commercial scale and has created tangible value for our partner, Teva" said Peter Hecht, CEO of Microbia. "Our Precision Engineering(TM) business is clearly gaining momentum, with partnerships spanning pharmaceuticals and fine chemicals." Microbia (www.microbia.com) is a privately held biotechnology company using a systems-based approach to making breakthrough drugs and biomanufacturing processes. The Company is pursuing development of novel anti-infectives and products for other human therapeutic indications, and is applying Precision Engineering(TM) to improve biomanufacturing efficiencies for collaborators in the pharmaceutical and chemical industries. Microbia has raised $59 million in private equity financing and is located in Cambridge, Mass.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next